|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2001-5-1
|
|
pubmed:abstractText |
The beneficial effects of spironolactone are additive to those of ACE inhibitors among patients with heart failure and/or hypertension; however, it is essential to identify patients prone to develop serious hyperkalemia during combined treatment and to evaluate the associated morbidity and mortality.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0002-9343
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
438-41
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11331054-Aged,
pubmed-meshheading:11331054-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:11331054-Creatinine,
pubmed-meshheading:11331054-Diuretics,
pubmed-meshheading:11331054-Dose-Response Relationship, Drug,
pubmed-meshheading:11331054-Drug Interactions,
pubmed-meshheading:11331054-Female,
pubmed-meshheading:11331054-Humans,
pubmed-meshheading:11331054-Hyperkalemia,
pubmed-meshheading:11331054-Male,
pubmed-meshheading:11331054-Risk Factors,
pubmed-meshheading:11331054-Spironolactone
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
|
|
pubmed:affiliation |
Department of Internal Medicine, Renal Division, University Hospital, Gent, Belgium.
|
|
pubmed:publicationType |
Journal Article
|
